PL2040736T3 - Nowa formulacja do zwiększenia biodostępności neurturyny - Google Patents

Nowa formulacja do zwiększenia biodostępności neurturyny

Info

Publication number
PL2040736T3
PL2040736T3 PL07764869T PL07764869T PL2040736T3 PL 2040736 T3 PL2040736 T3 PL 2040736T3 PL 07764869 T PL07764869 T PL 07764869T PL 07764869 T PL07764869 T PL 07764869T PL 2040736 T3 PL2040736 T3 PL 2040736T3
Authority
PL
Poland
Prior art keywords
neurturin
new formulation
increasing bioavailability
bioavailability
increasing
Prior art date
Application number
PL07764869T
Other languages
English (en)
Inventor
Friedrich Harder
Matthias Austen
Original Assignee
Evotec Int Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evotec Int Gmbh filed Critical Evotec Int Gmbh
Publication of PL2040736T3 publication Critical patent/PL2040736T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PL07764869T 2006-06-26 2007-06-26 Nowa formulacja do zwiększenia biodostępności neurturyny PL2040736T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06013135A EP1872790A1 (en) 2006-06-26 2006-06-26 New formulation for increasing bioavailability of neurturin
EP07764869.9A EP2040736B1 (en) 2006-06-26 2007-06-26 New formulation for increasing bioavailability of neurturin
PCT/EP2007/005652 WO2008000447A1 (en) 2006-06-26 2007-06-26 New formulation for increasing bioavailability of neurturin

Publications (1)

Publication Number Publication Date
PL2040736T3 true PL2040736T3 (pl) 2015-04-30

Family

ID=37440830

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07764869T PL2040736T3 (pl) 2006-06-26 2007-06-26 Nowa formulacja do zwiększenia biodostępności neurturyny

Country Status (9)

Country Link
US (3) US20090258829A1 (pl)
EP (3) EP1872790A1 (pl)
CY (1) CY1115938T1 (pl)
DK (1) DK2040736T3 (pl)
ES (1) ES2527093T3 (pl)
PL (1) PL2040736T3 (pl)
PT (1) PT2040736E (pl)
SI (1) SI2040736T1 (pl)
WO (1) WO2008000447A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050222070A1 (en) 2002-05-29 2005-10-06 Develogen Aktiengesellschaft Fuer Entwicklungsbiologische Forschung Pancreas-specific proteins
PL1694354T3 (pl) 2003-11-27 2009-12-31 Develogen Ag Sposób zapobiegania i leczenia cukrzycy za pomocą neurturyny
BRPI0819220A2 (pt) * 2007-11-05 2019-02-26 Develogen Aktiengessellschaft proteína neurturina ou fragmento da mesma, sua composição farmacêutica e uso
US8445432B2 (en) 2009-10-30 2013-05-21 Ntf Therapeutics Inc Neurturin molecules
US9127083B2 (en) 2009-10-30 2015-09-08 Ntf Therapeutics, Inc. Neurturin molecules
CN106727289A (zh) * 2016-11-11 2017-05-31 上海雅本化学有限公司 一种磺达肝癸钠组合物注射液及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
ATE135370T1 (de) 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
EP1241258A3 (en) 1989-10-16 2003-12-10 Amgen Inc. Stem cell factor
AU1052492A (en) * 1991-01-31 1992-08-06 Farmitalia Carlo Erba S.R.L. Synergistic composition comprising a fibroblast growth factor and a sulfated polylsaccharide, for use as antiviral agent
CA2119463C (en) 1991-09-20 2003-09-16 Leu-Fen H. Lin Glial cell line-derived neutrophic factor
US5464815A (en) * 1993-09-08 1995-11-07 Genentech, Inc. Inhibition of heparin-binding
US5739307A (en) 1995-08-28 1998-04-14 Washington University Polynucleotide encoding neurturin neurotrophic factor
US6043221A (en) 1997-07-30 2000-03-28 Amgen Inc. Method for preventing and treating hearing loss using a neuturin protein product
FR2812551B1 (fr) * 2000-08-07 2003-03-28 Virsol Forme pharmaceutique comprenant un materiau support a base de methylidene malonate et un facteur de regulation cellulaire
AU2002355160A1 (en) 2001-07-24 2003-02-17 Novo Nordisk A/S Method for making acylated polypeptides
EP1507553A2 (en) 2002-05-29 2005-02-23 DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung Pancreas-specific proteins
PL1694354T3 (pl) * 2003-11-27 2009-12-31 Develogen Ag Sposób zapobiegania i leczenia cukrzycy za pomocą neurturyny
DK2019683T4 (da) * 2006-04-25 2022-08-29 Univ California Indgivelse af vækstfaktorer til behandling af CNS-lidelser

Also Published As

Publication number Publication date
EP1872790A1 (en) 2008-01-02
US20090258829A1 (en) 2009-10-15
EP2371379A3 (en) 2012-12-26
WO2008000447A1 (en) 2008-01-03
US20140162948A1 (en) 2014-06-12
DK2040736T3 (en) 2015-01-12
US20130053313A1 (en) 2013-02-28
CY1115938T1 (el) 2017-01-25
EP2371379A2 (en) 2011-10-05
PT2040736E (pt) 2014-12-31
EP2040736B1 (en) 2014-12-10
ES2527093T3 (es) 2015-01-20
EP2040736A1 (en) 2009-04-01
SI2040736T1 (sl) 2015-03-31

Similar Documents

Publication Publication Date Title
HK1220378A1 (zh) 具有所需生物利用度的藥物組合物
IL198847A0 (en) New process for the preparation of 2-imino-thiazolidin-4-one derivatives
EP2001500A4 (en) FORMULATIONS FOR ECALLANTIDE
IL201189A0 (en) Fluorinated derivatives of deferiprone
HK1110219A1 (en) Use of prodrugs for ocular intravitreous administration
HK1134902A1 (en) Compounds a-r-x for the manufacture of pharmaceutical preparations
GB0624963D0 (en) Derivatives of 188-Glycyrrhetinic Acid
EP2216325A4 (en) PROCESS FOR THE PREPARATION OF TRIFLUOROMETHANESULFONYL FLUORIDE
ZA201003227B (en) Novel neurturin conjugates for pharmaceutical use
SI2040736T1 (sl) Nova formulacija za poveäśanje biodostopnosti neurturina
ZA201004322B (en) Use of tetramic acid derivatives for controlling nematodes
PL2102174T3 (pl) Sposób wytwarzania pochodnych podstawionych cyjanofenoksy-pirymidynyloksyfenyloakrylanów
IL205082A0 (en) Process for the preparation of tetranorlabdane derivatives
PL2171061T3 (pl) Preparat esterazy
HUP0700756A2 (en) Process for the preparation of pharmaceutical intermediers
EP2173695A4 (en) PROCESS FOR THE PREPARATION OF CIS-4-TERT.-BUTYLCYCLOHEXANOL
EP2175918A4 (en) MANUFACTURE OF COMPONENTS OF MEDICAL DISTRIBUTORS
EG26107A (en) Way to prepare medicine Alandral
SI2219611T1 (sl) Farmacevtske oblike za sproĺ äśanje aktivnih spojin
IL198836A0 (en) Processes for preparation of 9-haloacetamidomidominocyclines
GB2464071B (en) Coating formulation for combating cross-infection
SI2319517T1 (sl) Uporaba predzdravil za okularno intravitrealno administracijo
SI1864667T1 (sl) Uporaba predzdravil za okularno intravitrealno administracijo
EP2250178A4 (en) IMPROVED PROCESS FOR THE PREPARATION OF TRIAZOL-BENZODIAZEPINE DERIVATIVES
HU0700465D0 (en) Process for the preparation of n-[(4-phenyl)-methyl]-piperazine derivatives